Min Jeong Wang
Research Subjects
Min Jeong Wang has a total of 73 co-authors. Here are the top co-authors by number of shared publications:
- SangYun Kim
Seoul National University Bundang Hospital
15 shared publications - Dong Won Yang
Department of Neurology, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
12 shared publications - Kee Hyung Park
Department of Neurology, Gachon University Gil Medical Center, Gachon University College of Medicine, Incheon, Korea
12 shared publications - Jee Hyang Jeong
Department of Neurology, College of Medicine, Ewha Womans University, Seoul, Republic of Korea
10 shared publications - Seong Hye Choi
Department of Neurology, Inha University College of Medicine, Incheon 22332, Republic of Korea
8 shared publications - Yun Jeong Hong
Department of Neurology, Uijeongbu St. Mary’s Hospital, The Catholic University of Korea, Seoul, Korea
8 shared publications
Latest Publications
- 23 March 2026
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 110 (4) , 1961-1970
Plasma glial fibrillary acidic protein as a potential biomarker for differentiating amyloid-negative subjective cognitive decline and mild cognitive impairment
Background: Differentiating subjective cognitive decline (SCD) from mild cognitive impairment (MCI) in amyloid-negative (A−) individuals is clinically relevant for early evaluation along the Alzheimer's disease (AD) pathway. Objective: To assess whether plasma biomarkers discriminate between A−SCD and A−MCI and compare their performance. Methods: We studied 114 amyloid PET–negative participants (93 A−SCD, 21 A−MCI) aged ≥60 years from multicenter cohorts. Plasma Aβ 42 /Aβ 40 ratio, glial fibrillary acidic protein (GFAP), neurofilament light chain (NFL), and phosphorylated tau 181 (pTau181) were measured using Simoa. Associations with MCI were estimated with logistic regression; discrimination was assessed by ROC analysis with AUCs and pairwise AUC comparisons using 1000 bootstrap resamples. Results: Standardized log (GFAP) was associated with MCI in univariate analysis (OR 2.32; 95% CI 1.35–4.00; p = 0.002) and after adjustment for age and sex (OR 2.45; 1.27–4.74; p = 0.008). GFAP showed moderate discrimination (AUC 0.71; 0.59–0.82), whereas Aβ 42 /Aβ 40 , NFL, and pTau181 did not. Pairwise AUC differences favored GFAP over Aβ 42 /Aβ 40 (ΔAUC 0.34; p = 0.020), NFL (0.21; p = 0.032), and pTau181 (0.29; p = 0.005). Conclusions: In this A− cohort, plasma GFAP was the most informative biomarker for distinguishing MCI from SCD, likely reflecting astrocytic activation. Given modest accuracy and limited disease specificity, GFAP may be most useful as part of a multimodal panel rather than a stand-alone test.
- 23 March 2026
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 110 (4) , 1961-1970
Plasma glial fibrillary acidic protein as a potential biomarker for differentiating amyloid-negative subjective cognitive decline and mild cognitive impairment
Background: Differentiating subjective cognitive decline (SCD) from mild cognitive impairment (MCI) in amyloid-negative (A−) individuals is clinically relevant for early evaluation along the Alzheimer's disease (AD) pathway. Objective: To assess whether plasma biomarkers discriminate between A−SCD and A−MCI and compare their performance. Methods: We studied 114 amyloid PET–negative participants (93 A−SCD, 21 A−MCI) aged ≥60 years from multicenter cohorts. Plasma Aβ 42 /Aβ 40 ratio, glial fibrillary acidic protein (GFAP), neurofilament light chain (NFL), and phosphorylated tau 181 (pTau181) were measured using Simoa. Associations with MCI were estimated with logistic regression; discrimination was assessed by ROC analysis with AUCs and pairwise AUC comparisons using 1000 bootstrap resamples. Results: Standardized log (GFAP) was associated with MCI in univariate analysis (OR 2.32; 95% CI 1.35–4.00; p = 0.002) and after adjustment for age and sex (OR 2.45; 1.27–4.74; p = 0.008). GFAP showed moderate discrimination (AUC 0.71; 0.59–0.82), whereas Aβ 42 /Aβ 40 , NFL, and pTau181 did not. Pairwise AUC differences favored GFAP over Aβ 42 /Aβ 40 (ΔAUC 0.34; p = 0.020), NFL (0.21; p = 0.032), and pTau181 (0.29; p = 0.005). Conclusions: In this A− cohort, plasma GFAP was the most informative biomarker for distinguishing MCI from SCD, likely reflecting astrocytic activation. Given modest accuracy and limited disease specificity, GFAP may be most useful as part of a multimodal panel rather than a stand-alone test.
- Open Access
- 1 January 2026
- Published by XMLink in Journal of Clinical Neurology
- Vol. 22 (5) , 560-572
Comparative Prognostic Performance of Hippocampal Volume and Plasma Biomarkers in Amyloid-Negative Subjective Cognitive Decline: A Four-Year Follow-up
Yoon B, et al. J Clin Neurol. 2026 Sep;22(5):560-572. https://doi.org/10.3988/jcn.2025.0659
- 1 January 2026
- Published by XMLink in Journal of Clinical Neurology
- Vol. 22 (5) , 560-572
Open AccessComparative Prognostic Performance of Hippocampal Volume and Plasma Biomarkers in Amyloid-Negative Subjective Cognitive Decline: A Four-Year Follow-up
Yoon B, et al. J Clin Neurol. 2026 Sep;22(5):560-572. https://doi.org/10.3988/jcn.2025.0659
- Open Access
- 1 January 2026
- Published by XMLink in Journal of Korean Medical Science
- Vol. 41 (25) , e184
APOE Genotype Modifies the Predictive Performance of Plasma Biomarkers for Amyloid Plaque Burden in Subjective Cognitive Decline
Apolipoprotein E (APOE) ε4 is a well-known risk factor for Alzheimer’s disease (AD), with ε4 carriers exhibiting distinct clinical and biological characteristics compared to non-carriers. This study investigated whether the predictive performance of plasma biomarkers for amyloid positron emission tomography (PET) outcomes varies by APOE ε4 carrier status in individuals with subjective cognitive decline (SCD). We retrospectively analyzed baseline data from the Cohort Study to Identify Predictors for the Clinical Progression to Mild Cognitive Impairment or Dementia from Subjective Cognitive Decline. Plasma levels of the amyloid beta (Aβ) 42/40 ratio, glial fibrillary acidic protein (GFAP), neurofilament light chain (NfL), and phosphorylated tau (pTau) 181 were quantified using Single Molecule Array technology. We assessed predictive performance of plasma biomarkers for amyloid PET outcomes using receiver operating characteristic analysis and linear regression models. The study included 104 participants, with 20 APOE ε4 carriers and 84 non-carriers. Among ε4 carriers, NfL (area under the curve [AUC] = 0.909), GFAP (AUC = 0.904), and pTau181 (AUC = 0.828) showed the highest predictive accuracy. For non-carriers, the most predictive biomarkers were pTau181/Aβ42 (AUC = 0.872), Aβ42/Aβ40 (AUC = 0.794), and pTau181 (AUC = 0.761). Significant interactions between APOE and biomarkers were noted for GFAP (P = 0.005) and NfL (P = 0.010) in predicting amyloid plaque burden. Plasma biomarkers exhibit differential predictive performance for amyloid pathology based on APOE genotype, with GFAP and NfL showing interaction with APOE genotype. These findings suggest the importance of considering APOE genotype when interpreting plasma biomarker results for AD diagnosis in individuals with SCD. Clinical Research Information Service Identifier: KCT0003397
- 1 January 2026
- Published by XMLink in Journal of Korean Medical Science
- Vol. 41 (25) , e184
Open AccessAPOE Genotype Modifies the Predictive Performance of Plasma Biomarkers for Amyloid Plaque Burden in Subjective Cognitive Decline
Apolipoprotein E (APOE) ε4 is a well-known risk factor for Alzheimer’s disease (AD), with ε4 carriers exhibiting distinct clinical and biological characteristics compared to non-carriers. This study investigated whether the predictive performance of plasma biomarkers for amyloid positron emission tomography (PET) outcomes varies by APOE ε4 carrier status in individuals with subjective cognitive decline (SCD). We retrospectively analyzed baseline data from the Cohort Study to Identify Predictors for the Clinical Progression to Mild Cognitive Impairment or Dementia from Subjective Cognitive Decline. Plasma levels of the amyloid beta (Aβ) 42/40 ratio, glial fibrillary acidic protein (GFAP), neurofilament light chain (NfL), and phosphorylated tau (pTau) 181 were quantified using Single Molecule Array technology. We assessed predictive performance of plasma biomarkers for amyloid PET outcomes using receiver operating characteristic analysis and linear regression models. The study included 104 participants, with 20 APOE ε4 carriers and 84 non-carriers. Among ε4 carriers, NfL (area under the curve [AUC] = 0.909), GFAP (AUC = 0.904), and pTau181 (AUC = 0.828) showed the highest predictive accuracy. For non-carriers, the most predictive biomarkers were pTau181/Aβ42 (AUC = 0.872), Aβ42/Aβ40 (AUC = 0.794), and pTau181 (AUC = 0.761). Significant interactions between APOE and biomarkers were noted for GFAP (P = 0.005) and NfL (P = 0.010) in predicting amyloid plaque burden. Plasma biomarkers exhibit differential predictive performance for amyloid pathology based on APOE genotype, with GFAP and NfL showing interaction with APOE genotype. These findings suggest the importance of considering APOE genotype when interpreting plasma biomarker results for AD diagnosis in individuals with SCD. Clinical Research Information Service Identifier: KCT0003397
- Open Access
- 1 January 2026
- Published by XMLink in Journal of Korean Medical Science
- Vol. 41 (3) , e36
Hand Grip Strength Predicts Cognitive Decline in Subjective Cognitive Decline: 2-Year Follow-Up Results
Lim EY, et al. J Korean Med Sci. 2026 Jan;41(3):e36. https://doi.org/10.3346/jkms.2026.41.e36
- 1 January 2026
- Published by XMLink in Journal of Korean Medical Science
- Vol. 41 (3) , e36
Open AccessHand Grip Strength Predicts Cognitive Decline in Subjective Cognitive Decline: 2-Year Follow-Up Results
Lim EY, et al. J Korean Med Sci. 2026 Jan;41(3):e36. https://doi.org/10.3346/jkms.2026.41.e36
- Open Access
- 29 December 2025
- Published by Springer Nature in Alzheimer's Research & Therapy
- Vol. 17 (1) , 265
EEG-based detection of early functional brain changes in subjective cognitive decline: a prospective cohort study
Background: Subjective cognitive decline (SCD) has been recognized as a preclinical stage of Alzheimer’s disease. However, the identification of early functional brain changes remains challenging. This study investigated the functional brain changes in SCD using longitudinal EEG and evaluate the feasibility of EEG features as scalable biomarkers for identifying amyloid burden and cognitive decline using an interpretable machine learning framework. Methods: We analyzed 120 individuals with SCD enrolled in a multicenter prospective cohort (the CoSCo study) at baseline and after a 2-year follow-up. Participants were classified as amyloid-positive (A + SCD) or amyloid-negative (A − SCD). Spectral power and graph theory-based network analyses were conducted. Also, we trained machine learning classifiers to distinguish between the groups and interpreted the predictions of classifiers using SHAP. Results: At both baseline and follow-up, the A + SCD group exhibited elevated low-frequency (delta and theta) activity and reduced alpha activity compared to the A − SCD group. The EEG-based classifiers distinguished A + SCD from A-SCD individuals with high performance, outperforming a classifier based on demographic data. The results of SHAP analysis confirmed the importance and relative contribution of selected EEG features. Conclusions: Longitudinal EEG, when combined with interpretable machine learning, can detect and track the functional alterations of brain related to amyloid pathology in preclinical AD. Our findings support the feasibility of EEG as a non-invasive, scalable, and sensitive biomarker for risk stratification, before overt cognitive impairment emerges. Trial registration: This study was registered at the Clinical Research Information Service (CRIS) (cris.nih.go.kr/cris; # KCT0003397, Registration Date: December 21, 2018).
- 29 December 2025
- Published by Springer Nature in Alzheimer's Research & Therapy
- Vol. 17 (1) , 265
Open AccessEEG-based detection of early functional brain changes in subjective cognitive decline: a prospective cohort study
Background: Subjective cognitive decline (SCD) has been recognized as a preclinical stage of Alzheimer’s disease. However, the identification of early functional brain changes remains challenging. This study investigated the functional brain changes in SCD using longitudinal EEG and evaluate the feasibility of EEG features as scalable biomarkers for identifying amyloid burden and cognitive decline using an interpretable machine learning framework. Methods: We analyzed 120 individuals with SCD enrolled in a multicenter prospective cohort (the CoSCo study) at baseline and after a 2-year follow-up. Participants were classified as amyloid-positive (A + SCD) or amyloid-negative (A − SCD). Spectral power and graph theory-based network analyses were conducted. Also, we trained machine learning classifiers to distinguish between the groups and interpreted the predictions of classifiers using SHAP. Results: At both baseline and follow-up, the A + SCD group exhibited elevated low-frequency (delta and theta) activity and reduced alpha activity compared to the A − SCD group. The EEG-based classifiers distinguished A + SCD from A-SCD individuals with high performance, outperforming a classifier based on demographic data. The results of SHAP analysis confirmed the importance and relative contribution of selected EEG features. Conclusions: Longitudinal EEG, when combined with interpretable machine learning, can detect and track the functional alterations of brain related to amyloid pathology in preclinical AD. Our findings support the feasibility of EEG as a non-invasive, scalable, and sensitive biomarker for risk stratification, before overt cognitive impairment emerges. Trial registration: This study was registered at the Clinical Research Information Service (CRIS) (cris.nih.go.kr/cris; # KCT0003397, Registration Date: December 21, 2018).
- 6 February 2025
- Published by S. Karger AG in Dementia and Geriatric Cognitive Disorders
- Vol. 54 (4) , 246-254
Longitudinal Analysis of Objective and Self-Reported Cognitive Functions in Individuals with Subjective Cognitive Decline
Introduction: Subjective cognitive decline (SCD) is considered a preclinical manifestation of Alzheimer’s disease (AD). Recent research suggests that subtle cognitive changes in SCD are linked to an increased risk of clinical decline. This study investigates the longitudinal trajectories of both objective and self-reported cognitive functions in individuals with SCD, with a focus on the impact of subtle cognitive impairment (SCI). Methods: A total of 107 individuals with SCD, with at least two annual follow-ups, were included in this study. We analyzed the trajectories of both objective and subjective cognitive functions, assessed changes in medial temporal lobe regional volumes, and compared baseline AD biomarkers between SCD individuals with SCI (n = 22, SCI group) and without SCI (n = 85). Results: SCD individuals with SCI showed a faster decline in objective cognitive function over time compared to those without SCI, who exhibited cognitive improvement. Self-reported cognitive complaints showed no differences between groups at baseline or in annual changes over time. The SCI group had lower baseline entorhinal cortical volumes and greater volume reductions over time and also exhibited more abnormalities in AD biomarkers, including higher amyloid PET positivity, a lower Aβ 42/40 ratio, and elevated p-tau181. Conclusion: SCI status in SCD individuals is associated with significant cognitive decline, along with more abnormal AD biomarkers. These findings suggest that early identification of SCI status in individuals with SCD may improve the prediction of cognitive decline. However, self-reported cognitive complaints may have a limited role in monitoring clinical changes in SCD.
- 6 February 2025
- Published by S. Karger AG in Dementia and Geriatric Cognitive Disorders
- Vol. 54 (4) , 246-254
Longitudinal Analysis of Objective and Self-Reported Cognitive Functions in Individuals with Subjective Cognitive Decline
Introduction: Subjective cognitive decline (SCD) is considered a preclinical manifestation of Alzheimer’s disease (AD). Recent research suggests that subtle cognitive changes in SCD are linked to an increased risk of clinical decline. This study investigates the longitudinal trajectories of both objective and self-reported cognitive functions in individuals with SCD, with a focus on the impact of subtle cognitive impairment (SCI). Methods: A total of 107 individuals with SCD, with at least two annual follow-ups, were included in this study. We analyzed the trajectories of both objective and subjective cognitive functions, assessed changes in medial temporal lobe regional volumes, and compared baseline AD biomarkers between SCD individuals with SCI (n = 22, SCI group) and without SCI (n = 85). Results: SCD individuals with SCI showed a faster decline in objective cognitive function over time compared to those without SCI, who exhibited cognitive improvement. Self-reported cognitive complaints showed no differences between groups at baseline or in annual changes over time. The SCI group had lower baseline entorhinal cortical volumes and greater volume reductions over time and also exhibited more abnormalities in AD biomarkers, including higher amyloid PET positivity, a lower Aβ 42/40 ratio, and elevated p-tau181. Conclusion: SCI status in SCD individuals is associated with significant cognitive decline, along with more abnormal AD biomarkers. These findings suggest that early identification of SCI status in individuals with SCD may improve the prediction of cognitive decline. However, self-reported cognitive complaints may have a limited role in monitoring clinical changes in SCD.
- Open Access
- 1 January 2024
- Published by XMLink in Journal of Cognitive Intervention and Digital Health
- Vol. 3 (1) , 19-27
The Effect of Tablet-Based Digital Cognitive Training Program for Older Adults in Japan: A Pilot Study
Lee D, et al. J Cogn Interv Digit Health. 2024 Dec;3(1):19-27. https://doi.org/10.58558/jcd.2024.3.1.19
- 1 January 2024
- Published by XMLink in Journal of Cognitive Intervention and Digital Health
- Vol. 3 (1) , 19-27
Open AccessThe Effect of Tablet-Based Digital Cognitive Training Program for Older Adults in Japan: A Pilot Study
Lee D, et al. J Cogn Interv Digit Health. 2024 Dec;3(1):19-27. https://doi.org/10.58558/jcd.2024.3.1.19
- Open Access
- 1 January 2024
- Published by XMLink in Dementia and Neurocognitive Disorders
- Vol. 23 (1) , 22-29
Relationship Between Amyloid Positivity and Sleep Characteristics in the Elderly With Subjective Cognitive Decline
Alzheimer’s disease (AD) is a neurodegenerative disease characterized by a progressive decline in cognition and performance of daily activities. Recent studies have attempted to establish the relationship between AD and sleep. It is believed that patients with AD pathology show altered sleep characteristics years before clinical symptoms appear. This study evaluated the differences in sleep characteristics between cognitively asymptomatic patients with and without some amyloid burden. Sleep characteristics of 76 subjects aged 60 years or older who were diagnosed with subjective cognitive decline (SCD) but not mild cognitive impairment (MCI) or AD were measured using Fitbit® Alta HR, a wristwatch-shaped wearable device. Amyloid deposition was evaluated using brain amyloid plaque load (BAPL) and global standardized uptake value ratio (SUVR) from fluorine-18 florbetaben positron emission tomography. Each component of measured sleep characteristics was analyzed for statistically significant differences between the amyloid-positive group and the amyloid-negative group. Of the 76 subjects included in this study, 49 (64.5%) were female. The average age of the subjects was 70.72±6.09 years when the study started. 15 subjects were classified as amyloid-positive based on BAPL. The average global SUVR was 1.598±0.263 in the amyloid-positive group and 1.187±0.100 in the amyloid-negative group. Time spent in slow-wave sleep (SWS) was significantly lower in the amyloid-positive group (39.4±13.1 minutes) than in the amyloid-negative group (49.5±13.1 minutes) (p=0.009). This study showed that SWS is different between the elderly SCD population with and without amyloid positivity. How SWS affects AD pathology requires further research.
- 1 January 2024
- Published by XMLink in Dementia and Neurocognitive Disorders
- Vol. 23 (1) , 22-29
Open AccessRelationship Between Amyloid Positivity and Sleep Characteristics in the Elderly With Subjective Cognitive Decline
Alzheimer’s disease (AD) is a neurodegenerative disease characterized by a progressive decline in cognition and performance of daily activities. Recent studies have attempted to establish the relationship between AD and sleep. It is believed that patients with AD pathology show altered sleep characteristics years before clinical symptoms appear. This study evaluated the differences in sleep characteristics between cognitively asymptomatic patients with and without some amyloid burden. Sleep characteristics of 76 subjects aged 60 years or older who were diagnosed with subjective cognitive decline (SCD) but not mild cognitive impairment (MCI) or AD were measured using Fitbit® Alta HR, a wristwatch-shaped wearable device. Amyloid deposition was evaluated using brain amyloid plaque load (BAPL) and global standardized uptake value ratio (SUVR) from fluorine-18 florbetaben positron emission tomography. Each component of measured sleep characteristics was analyzed for statistically significant differences between the amyloid-positive group and the amyloid-negative group. Of the 76 subjects included in this study, 49 (64.5%) were female. The average age of the subjects was 70.72±6.09 years when the study started. 15 subjects were classified as amyloid-positive based on BAPL. The average global SUVR was 1.598±0.263 in the amyloid-positive group and 1.187±0.100 in the amyloid-negative group. Time spent in slow-wave sleep (SWS) was significantly lower in the amyloid-positive group (39.4±13.1 minutes) than in the amyloid-negative group (49.5±13.1 minutes) (p=0.009). This study showed that SWS is different between the elderly SCD population with and without amyloid positivity. How SWS affects AD pathology requires further research.
- Open Access
- 1 January 2023
- Published by XMLink in Journal of Clinical Neurology
- Vol. 19 (5) , 447-453
Clinical Significance of Physical Frailty in Subjects With Subjective Cognitive Decline: A Prospective Study With Amyloid PET Data
Lim EY, et al. J Clin Neurol. 2023 Jun;19:e39. https://doi.org/10.3988/jcn.2022.0353
- 1 January 2023
- Published by XMLink in Journal of Clinical Neurology
- Vol. 19 (5) , 447-453
Open AccessClinical Significance of Physical Frailty in Subjects With Subjective Cognitive Decline: A Prospective Study With Amyloid PET Data
Lim EY, et al. J Clin Neurol. 2023 Jun;19:e39. https://doi.org/10.3988/jcn.2022.0353
- Open Access
- 31 October 2022
- Published by XMLink in Dementia and Neurocognitive Disorders
- Vol. 21 (4) , 147-161
Study Design and Baseline Results in a Cohort Study to Identify Predictors for the Clinical Progression to Mild Cognitive Impairment or Dementia From Subjective Cognitive Decline (CoSCo) Study
Ho S, et al. Dement Neurocogn Disord. 2022 Oct;21(4):147-161. https://doi.org/10.12779/dnd.2022.21.4.147
- 31 October 2022
- Published by XMLink in Dementia and Neurocognitive Disorders
- Vol. 21 (4) , 147-161
Open AccessStudy Design and Baseline Results in a Cohort Study to Identify Predictors for the Clinical Progression to Mild Cognitive Impairment or Dementia From Subjective Cognitive Decline (CoSCo) Study
Ho S, et al. Dement Neurocogn Disord. 2022 Oct;21(4):147-161. https://doi.org/10.12779/dnd.2022.21.4.147